Related Experiment Videos
[Angiogenesis: prognostic marker in prostatic cancer].
M Borre1, I B Offersen, B Nerstrøm
1Arhus Universitetshospital, Kraeftens Bekaempelse, afdeling for eksperimentel klinisk onkologi.
Ugeskrift for Laeger
|July 21, 1999
Summary
Microvessel density (MVD) in prostate cancer tumors at diagnosis predicts patient survival. Higher MVD indicates poorer disease-specific survival, offering prognostic value for prostate cancer outcomes.
Area of Science:
- Oncology
- Pathology
- Vascular Biology
Context:
- Prostate cancer prognosis is crucial for treatment decisions.
- Angiogenesis, the formation of new blood vessels, is implicated in tumor progression.
- Microvessel density (MVD) is a potential biomarker for tumor aggressiveness.
Purpose:
- To investigate the correlation between microvessel density (MVD) at diagnosis and disease-specific survival in prostate cancer patients.
- To determine if MVD can serve as a prognostic indicator in a non-curatively treated population.
Summary:
- Microvessel density (MVD) was quantified immunohistochemically using factor VIII-related antigen in 221 prostate cancer patients' diagnostic tumor samples.
- Maximal MVD was measured within a 0.25 mm² area, with a median of 43 (range 16-151).
- MVD showed a statistically significant correlation with clinicopathological characteristics and disease-specific survival.
Impact:
- Multivariate analysis confirmed MVD as a significant predictor of disease-specific survival in the overall and clinically localized prostate cancer populations.
- Quantification of angiogenesis through MVD reflects the spontaneous clinical outcome of prostate cancer.
- MVD assessment offers valuable prognostic information for prostate cancer management.